Ersatta: Phase Ib/IIa data

Top-line data from 42 Type I diabetics with signs of peripheral neuropathy in the Phase IIa portion of a double-blind, U.S. Phase Ib/IIa trial showed that subcutaneous Ersatta significantly improved

Read the full 305 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE